Treatment of EAE mice with Treg, G-MDSC and IL-2: a new insight into cell therapy for multiple sclerosis

Immunotherapy. 2022 Jul;14(10):789-798. doi: 10.2217/imt-2021-0045. Epub 2022 Jun 8.

Abstract

Background: This study investigates the therapeutic and protective effects of Tregs, myeloid-derived suppressor cells (MDSCs) and IL-2 on multiple sclerosis (MS) disease model. Materials & methods: C57BL/6 mice were immunized to develop an experimental autoimmune encephalomyelitis (EAE) model. We then investigated effects of pre- and post-treatment EAE mice with Tregs, MDSCs and IL-2 on inflammation and demyelination in brain tissue, and on the number of Treg, granulocytic-MDSC and Th-17 cells in spleen. Results: Pre- and post-treatment of EAE mice by Tregs, MDSCs and IL-2 resulted in no weight change, reduced Th-17 cells and suppression of pathological properties. Conclusion: Pre- and post-treatment of immunized mice by Tregs, MDSCs and IL-2 prevent EAE induction.

Keywords: IL-2; MDSC; Treg cell; experimental autoimmune encephalomyelitis; multiple sclerosis.

Plain language summary

This study investigates the therapeutic and protective effects of suppressive immune cells and pivotal cytokines on multiple sclerosis disease model. In this study, mice were immunized to develop experimental autoimmune model. We then investigated effects of pre- and post-treatment model mice with suppressive immune cells and pivotal cytokines on immunomodulatory and pro-inflammatory cells. Pre- and post-treatment of model mice resulted in no weight change, reduced pro-inflammatory cells and suppression of undesired pathological properties.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Cell- and Tissue-Based Therapy
  • Cytokines
  • Encephalomyelitis, Autoimmune, Experimental* / therapy
  • Interleukin-2
  • Mice
  • Mice, Inbred C57BL
  • Multiple Sclerosis* / therapy
  • Myeloid-Derived Suppressor Cells*
  • T-Lymphocytes, Regulatory

Substances

  • Cytokines
  • Interleukin-2